170 related articles for article (PubMed ID: 31974704)
1. Risks and benefits of bevacizumab combined with chemotherapy for advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials.
Miyashita M; Hattori M; Takano T; Toyama T; Iwata H
Breast Cancer; 2020 May; 27(3):347-354. PubMed ID: 31974704
[TBL] [Abstract][Full Text] [Related]
2. Vascular-endothelial-growth-factor (VEGF) targeting therapies for endocrine refractory or resistant metastatic breast cancer.
Wagner AD; Thomssen C; Haerting J; Unverzagt S
Cochrane Database Syst Rev; 2012 Jul; (7):CD008941. PubMed ID: 22786517
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Bevacizumab in Pretreated Metastatic Breast Cancer: A Systematic Review and Meta-Analysis.
Li Z; Guo F; Han Y; Wang J; Xu B
Oncol Res Treat; 2022; 45(10):608-617. PubMed ID: 35882206
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.
Fang Y; Qu X; Cheng B; Chen Y; Wang Z; Chen F; Xiong B
Tumour Biol; 2015 Mar; 36(3):1933-41. PubMed ID: 25387808
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab combined with chemotherapy for ovarian cancer: an updated systematic review and meta-analysis of randomized controlled trials.
Wu YS; Shui L; Shen D; Chen X
Oncotarget; 2017 Feb; 8(6):10703-10713. PubMed ID: 27793044
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of targeted therapy in patients with previously untreated metastatic breast cancer: a systematic review and meta-analysis.
Kawalec P; Łopuch S; Mikrut A
Clin Breast Cancer; 2015 Apr; 15(2):90-100.e1. PubMed ID: 25441421
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of bevacizumab plus paclitaxel as first-line treatment for HER2-negative metastatic breast cancer: a meta-analysis of randomized controlled trials.
Wang X; Huang C; Li M; Gu Y; Cui Y; Li Y
Tumour Biol; 2014 May; 35(5):4841-8. PubMed ID: 24570182
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer.
Chan DLH; Segelov E; Wong RS; Smith A; Herbertson RA; Li BT; Tebbutt N; Price T; Pavlakis N
Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007047. PubMed ID: 28654140
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant Bevacizumab plus Chemotherapy versus Chemotherapy Alone to Treat Non-Metastatic Breast Cancer: A Meta-Analysis of Randomised Controlled Trials.
Cao L; Yao GY; Liu MF; Chen LJ; Hu XL; Ye CS
PLoS One; 2015; 10(12):e0145442. PubMed ID: 26717149
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Sun L; Ma JT; Zhang SL; Zou HW; Han CB
Med Oncol; 2015 Feb; 32(2):473. PubMed ID: 25603953
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab in combination with first-line chemotherapy in patients with metastatic colorectal cancer: a meta-analysis.
Hu W; Xu WS; Liao XF; He HJ
Minerva Chir; 2015 Dec; 70(6):451-8. PubMed ID: 26013763
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.
Valachis A; Polyzos NP; Patsopoulos NA; Georgoulias V; Mavroudis D; Mauri D
Breast Cancer Res Treat; 2010 Jul; 122(1):1-7. PubMed ID: 20063120
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials].
Han R; Wang G; Zhang Y; Zhao X
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2016 May; 45(4):379-386. PubMed ID: 27868411
[TBL] [Abstract][Full Text] [Related]
14. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients.
Miles DW; Diéras V; Cortés J; Duenne AA; Yi J; O'Shaughnessy J
Ann Oncol; 2013 Nov; 24(11):2773-80. PubMed ID: 23894038
[TBL] [Abstract][Full Text] [Related]
15. The use of bevacizumab in the modern era of targeted therapy for ovarian cancer: A systematic review and meta-analysis.
Liu S; Kasherman L; Fazelzad R; Wang L; Bouchard-Fortier G; Lheureux S; Krzyzanowska MK
Gynecol Oncol; 2021 May; 161(2):601-612. PubMed ID: 33546867
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bevacizumab combined with chemotherapy in the treatment of HER2-negative metastatic breast cancer: a network meta-analysis.
Sun Z; Lan X; Xu S; Li S; Xi Y
BMC Cancer; 2020 Mar; 20(1):180. PubMed ID: 32131770
[TBL] [Abstract][Full Text] [Related]
17. VEGF-A levels in bevacizumab-treated breast cancer patients: a systematic review and meta-analysis.
Santos LV; Cruz MR; Lopes Gde L; Lima JP
Breast Cancer Res Treat; 2015 Jun; 151(3):481-9. PubMed ID: 25947646
[TBL] [Abstract][Full Text] [Related]
18. Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer.
Vrdoljak E; Marschner N; Zielinski C; Gligorov J; Cortes J; Puglisi F; Aapro M; Fallowfield L; Fontana A; Inbar M; Kahan Z; Welt A; Lévy C; Brain E; Pivot X; Putzu C; González Martín A; de Ducla S; Easton V; von Minckwitz G
Ann Oncol; 2016 Nov; 27(11):2046-2052. PubMed ID: 27502725
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib alone or in combination with chemotherapy for the treatment of advanced breast cancer: A systematic review and meta-analysis.
Elgebaly A; Menshawy A; El Ashal G; Osama O; Ghanem E; Omar A; Negida A
Breast Dis; 2016 Jul; 36(2-3):91-101. PubMed ID: 27612040
[TBL] [Abstract][Full Text] [Related]
20. Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: Literature-based analysis of 24 randomized trials.
Liu L; Chen F; Zhao J; Yu H
Bull Cancer; 2016 Apr; 103(4):336-44. PubMed ID: 26874974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
